{"id":"NCT03874013","sponsor":"OPKO Health, Inc.","briefTitle":"Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency","officialTitle":"A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-07","primaryCompletion":"2020-03-06","completion":"2020-03-06","firstPosted":"2019-03-14","resultsPosted":"2021-08-12","lastUpdate":"2021-08-12"},"enrollment":44,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"OTHER"},"conditions":["Growth Hormone Deficiency"],"interventions":[{"type":"DRUG","name":"MOD-4023","otherNames":["Somatrogon"]},{"type":"DRUG","name":"Genotropin","otherNames":[]}],"arms":[{"label":"MOD-4023 Treatment Arm","type":"EXPERIMENTAL"},{"label":"Genotropin Treatment Arm","type":"ACTIVE_COMPARATOR"}],"summary":"Treatment of children with growth failure due to growth hormone deficiency (GHD).\n\nPrimary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese pre-pubertal children with GHD.\n\nSecondary\n\n• To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of three different doses of MOD-4023 in Japanese pre-pubertal children with GHD.","primaryOutcome":{"measure":"Annual Height Velocity (HV) After 12 Months","timeFrame":"12 months","effectByArm":[{"arm":"MOD-4023 Treatment Arm","deltaMin":9.78,"sd":1.59},{"arm":"Genotropin Treatment Arm","deltaMin":7.78,"sd":1.14}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":46,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":22},"commonTop":["Nasopharyngitis","Injection site pain","Influenza","Pyrexia","Pharyngitis"]}}